NASDAQ · BBNX
Healthcare · Medical - Equipment & Services
$17.58
Down-$0.60 (-3.39%)
Updated Oct 30, 2026, 1:47 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BBNX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
BBNX closed at $17.58 after 21 trading sessions, down 6.84% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $17.85 | $18.94 | $16.96 | $17.58 | 1.29M |
| Oct 28, 2026 | $18.715 | $20.07 | $17.1501 | $17.85 | 2.8M |
| Oct 27, 2026 | $20.50 | $22.29 | $20.40 | $21.39 | 1.44M |
| Oct 26, 2026 | $19.08 | $21.185 | $19.08 | $20.51 | 1.63M |
| Oct 23, 2026 | $19.38 | $19.54 | $18.8075 | $19.16 | 827.85K |
| Oct 22, 2026 | $18.40 | $19.375 | $18.23 | $19.34 | 685.2K |
| Oct 21, 2026 | $17.79 | $18.50 | $17.17 | $18.40 | 1.44M |
| Oct 20, 2026 | $16.98 | $18.055 | $16.87 | $17.74 | 656.73K |
| Oct 19, 2026 | $16.60 | $17.39 | $16.60 | $16.84 | 1.68M |
| Oct 16, 2026 | $17.42 | $17.53 | $16.32 | $16.35 | 660.85K |
| Oct 15, 2026 | $16.98 | $17.60 | $16.601 | $17.31 | 1.33M |
| Oct 14, 2026 | $17.35 | $17.54 | $16.72 | $16.87 | 892.92K |
| Oct 13, 2026 | $17.87 | $18.14 | $17.52 | $17.69 | 591.35K |
| Oct 12, 2026 | $17.94 | $18.56 | $17.71 | $17.86 | 820.83K |
| Oct 9, 2026 | $17.47 | $17.88 | $17.12 | $17.63 | 955.12K |
| Oct 8, 2026 | $17.96 | $18.04 | $17.07 | $17.43 | 1.11M |
| Oct 7, 2026 | $18.91 | $19.11 | $17.934 | $18.08 | 1.53M |
| Oct 6, 2026 | $18.91 | $19.24 | $18.305 | $18.63 | 922.81K |
| Oct 5, 2026 | $18.91 | $19.265 | $18.735 | $18.95 | 624.63K |
| Oct 2, 2026 | $18.87 | $19.26 | $18.27 | $18.96 | 515.08K |
| Oct 1, 2026 | $19.35 | $19.44 | $18.39 | $18.87 | 1.14M |
The latest Smart Investors Daily articles mentioning BBNX.
Company
Market Activity
Research & News
BBNX research
Company profile and research snapshot.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | Piper Sandler | Overweight | — |
| Oct 28, 2026 | TD Cowen | Hold | — |
| Oct 12, 2026 | Jefferies | Buy | — |
| Sep 24, 2026 | Truist Securities | Buy | — |
| Sep 23, 2026 | Wells Fargo | Overweight | — |
Generated Oct 29, 2026, 9:10 PM
Beta Bionics shares declined 1.51% following the release of its Q3 2026 earnings results, as investors reacted to mixed financial performance and updated guidance. While the company beat revenue expectations, a reported net loss and concerns about product timing weighed on sentiment.
Bottom line: Beta Bionics' Q3 results present a mixed picture—solid revenue performance is undermined by ongoing losses and questions about the timeline to sustained profitability and key product launches. Investors should monitor upcoming quarters for evidence of margin improvement and whether the company can accelerate toward breakeven while maintaining revenue growth momentum.
Yahoo · Oct 28, 2026
Beta Bionics (NASDAQ:BBNX) reported third-quarter net sales of $35.5 million, up about 30% from a year earlier, as new patient starts and recurring revenue from its pharmacy-channel user base supported growth. The company also raised the lower end of its full-year revenue outlook and outlined plans
SeekingAlpha · Oct 27, 2026
Beta Bionics, Inc. (BBNX) Q3 2026 Earnings Call October 27, 2026 4:30 PM EDTCompany ParticipantsBlake Beber - Head of Investor RelationsSean Saint -...
ChartMill · Oct 27, 2026
Beta Bionics Q3 revenue matched estimates, but shares fell as full-year guidance missed consensus and Mint/3D launch timing raised concerns.
Yahoo · Oct 27, 2026
IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2026 and updated its full year guidance for the year ending December 31, 2026. Third Quarter 2026 Financial Highlights & Key Metrics Net sales of $35.5 million, up 30% compared to $27.3 million in the third quarter of 2025. Durable Medical Equipment (DME) chan
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BBNX.
